CV Therapeutics' angina drug may reduce frequency of attacks

A large clinical trial of CV Therapeutics' Ranexa, for angina, appeared to reduce the frequency of attacks and improves the drug's prospects for FDA approval. The biotech firm had several previous setbacks that raised questions about Ranexa's effectiveness, but the most recent trial of 565 patients in Eastern Europe produced statistically significant results, according to the firm.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations